Research made to measure.

英国 - 食品加工

2024年09月13日

买

高的风险

目标: €1.00

积极因素 —

- ❖ 良好的行业前景
- ❖ 良好的管理
- ❖ 强大的品牌影响力
- ❖ 强大的客户关系

积极因素 —

- ❖ 市场渗透率低
- ❖ 通货膨胀
- ❖ 竞争风险
- ❖ 有限的定价权
- ❖ 流动性低

Rapid Nutrition PLC 平衡向上 – €1...!

- 交易看涨期权。我们维持对 Rapid Nutrition PLC (ALRPD.PA),但我们将 风险评级从 SPECULATIVE 调整至高。我们每股 1.00 欧元的目标价保持 不变。本月迄今,该股上涨了 68%,分别跑赢了下跌 2% 的同行和上涨 1.9% 的泛欧交易所 100 指数。我们建议在疲软时积累股票。
- 向上再平衡。在第二批 Atlas 可转换贷款终止后,公司对 2024 年以后的增长前景进行战略审查,进入中国,导致公司加快偿还约 570.1 欧元。这占未偿还可转换贷款的一半以上。剩余可转换贷款预计将在年底前支付。考虑到这一点,我们认为值得将 SPECULATIVE 的风险评级重新平衡至 HIGH。
- 亚太地区。我们相信,最近进军日本和韩国市场,将继续扩大公司在亚太地区的足迹。在我们看来,这为该公司提供了大量机会,以在未来几年占领 10-150 亿美元的健康市场市场份额。我们认为,健康消费者对Azurene 和 SystemLS 品牌产生了积极反应,相当于股东回报的增加。
- ▶ 我们仍然相信,管理层对植物基技术的坚定承诺应该会在 2024 年及以后 继续增加收入,从而提高 Rapid Nutrition PLC 的品牌价值。
- 利用波动性。我们预计,随着第三季度末的临近,市场将出现波动,我们将任何回调都视为积累股票的机会。我们维持买入中等风险和每股1.00 欧元的目标价。

每股收益 P/E 12 月 Ratio N/Ax 2023 \$-\$-\$-2024F N/Ax 2025E N/Ax 市场概况 52周范围 €0.02-0.30 每股收益增长率(3年) N/A% 平均交易量 (3个月) 1,828,651 息税折旧摊销前利润增长率 N/A% 在外流通股 56,560 M 净资产收益率(LTM) N/A% 51.9% 市值 €2,035.8 M 债务占总上限 浮动市值 €1,161.3 M 每股账面价值 €0.04 机构所有者 €0.00/0.0% 18.0% 指示股息/收益率 业内人士控股 N/A% 收入(LTM) \$A1,953 MM 股份浮动 57.0% 股票空头

Please refer to the global disclaimer of this research at the end of document.

ALRPD.PA: €0.04

N100: 1,462.92

CAC40: 7,435.07

ALASI*: 889.66

*Alternext All Share Index

高级股票分析师 **Lenny Zephirin** info@zephiringroup.com



同行分析跟踪器

尽管与康宝莱有限公司(HLF - 未评级)6.656亿欧元、如新企业公司(NUS - 未评级)3.407亿欧元、Shineco,Inc. (SISI - 未评级)450万欧元和 The Beauty Health Co. (SKIN-未评级)1.637 亿欧元相比,该公司的市场估值较低,但我们认为Rapid Nutrition PLC 在健康、草药和保健领域占据了利基地位。随着品牌知名度和消费者需求的不断增长,该公司向北美(美国)多元化的战略应该会非常成功;因此,该公司应该会在 2024 年看到市场估值有所改善。

市场估值正在改善...


图 1. Rapid Nutrition PLC 同行当前资本化分析(百万欧元)*

• • • • • • • • • • • • • • • • • • •					
Ticker	ALRPD	SISI	NUS	SKIN	HLF
Current Share Price	€ 0.04	€ 0.40	€ 6.86	€ 1.32	€ 6.61
Shares Outstanding	56.6	11.2	49.7	124.0	100.7
Market Capitalization	€ 2.0	€ 4.5	€ 340.7	€ 163.7	€ 665.6
- Cash & Short Term Investments	0.3	0.6	219.8	317.1	339.3
+ Total Debt	0.1	27.3	506.4	514.9	2,316.1
Total Enterprise Value (TEV)	€ 1.9	€ 31.2	€ 627.3	€ 361.5	€ 2,642.4
Book Value of Common Equity	0.1	32.6	622.4	62.8	(940.8)
+ Pref. Equity Min Int	-	9.7	-	-	-
+ Total Debt	0.1	27.3	506.4	514.9	2,316.1
Total Capital	€ 0.2	€ 69.7	€ 1,128.8	€ 577.7	€ 1,375.3
Share Statistics					
Float	32.3	9.5	48.7	80.6	70.1
% Held by Insiders	19.8%	15.8%	2.1%	8.2%	1.5%
% Held by Institutions	18.0%	0.1%	85.6%	65.3%	72.9%
% Float	57.0%	84.2%	98.0%	65.0%	69.6%

*Prices as of September 12, 2024. Peers: Herbalife Ltd. (HLF – Not Rated), Nu Skin Enterprises, Inc. (NUS – Not Rated), Shineco, Inc. (SISI – Not Rated), and The Beauty Health Co. (SKIN – Not Rated) \$1 = €0.92; 1AUD = €0.61. Source: Company data and The Zephirin Group, Inc. (ZGI) research

MTD, ALRPD。PA 股价上涨了 68.2%,而同行股价分别上涨了 2.0% 和泛欧交易所指数上涨了 1.9%.

图 2. Rapid Nutrition PLC 迄今为止的性能跟踪器



Note: N100 = Euronext 100 Index; Peers = HLF, NUS, SISI & SKIN. Source: Industry Data & The Zephirin Group, Inc. (ZGI) research




公司介绍

Rapid Nutrition PLC是一家天然保健公司,在英国,澳大利亚,美国和欧洲其他地区研究,开发和生产一系列基于科学的健康和保健产品。该公司以Leisa's Secret和SystemLS的品牌提供基于科学的健康食品补充剂。该公司还以Azurene的名义提供口服抗病毒治疗产品,以对抗流感和普通感冒。此外,该公司还以DiCED的名义提供在线健身流媒体服务,目前在大约54个国家/地区提供。截至2023年底,植物基约占总收入的59.0%,健康和补充产品约占总收入的41.0%。该公司在英国,澳大利亚,美国,巴西,法国,意大利,瑞士,沙特阿拉伯,加纳,韩国,牙买加和加勒比地区分销其产品。澳大利亚子公司(Rapid Nutrition Pty Ltd.)成立于2001年。英国母公司成立于2012年,总部位于英国伦敦。

风险

我们的投资结论和价格目标面临的风险包括: 1-全球经济急剧下滑, 2-不利的消费者行为变化, 3-低于预期的市场扩张, 4-流动性和5-对一个市场的高度依赖.

图 3. Rapid Nutrition PLC评级价格量图表*



Source: Industry data and The Zephirin Group, Inc. (ZGI) research *Split adjusted 1:1000

Date	Price	Target	Rating	Notable Reports	
09-Feb-22	€0.03	€1.00	Buy SR	Emerging Growth – €1.00!	
06-May-22	€0.07			The right path – €1.00!	
16-Jun-22	€0.03			Remain Optimistic – €1.00!	
30-Aug-22	€0.02			It's all about September!	



IMPORTANT GLOBAL DISCLAIMER:

This research is only an opinion and should not be construed as a suggestion. The opinion is provided without any kind of warranty.

Rating System: STRONG BUY — The stock, securities or shares are expected to achieve a total return of 20% or more over the next 12-18 months, or are expected to outperform its industry and the S&P 500. BUY — The stock, securities or shares are expected to achieve a total return of 15% or more over the next 12-18 months, or are expected to outperform its industry peers and the S&P 500. HOLO — The stock, securities or shares are expected to achieve a total return of 10% or less, or are expected to perform in-line with its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 6-12 months. SUSPENDED — The stock, securities or shares are temporarily suspended due to market events that made coverage impracticable. Small and mid-sized company stocks involve greater risks than those customarily associated with larger companies.

Risk Rating: LOW RISK (LR) — Return of 0-10%; MEDIUM RISK (MR) — Return of 0-20%; HIGH RISK (HR) — Return of 0-30% and SPECULATIVE RISK (SR) — Return of 0-50%. Distribution of Rating: Strong Buy = 0 (0.0%); Buy = 16 (35.6%); Hold = 10 (22.2%); Sell = 6 (13.3%); Strong Sell = 1 (2.2%), Suspended = 12 (26.7%).

All of the recommendation and views about the securities and companies in this report accurately reflect the personal views of the research analyst named on the cover of this report. In particular the report intended to promote the integrity of research including those designed to ensure the identification and avoidance of conflict of interest.

Note: A securities rating is not a recommendation to BUY, HOLD or SELL securities and may be subject to revision or withdrawal at any time. You acknowledge that the price of securities traded on the Public Regulated Securities Exchanges (i.e., NYSE, NASDAQ, AMEX, Canadian Securities Exchange, Euronext, SIX Swiss Exchange, Hong Kong Stock Exchange, Singapore Stock Exchange) are subject to investment risks, can and does fluctuate, and any individual security may experience upwards or downwards movements, and may even become valueless.

The Zéphirin Group, Inc. ("ZGI") is an independent global equity research company that is incorporated in the State of Delaware on November 2003. The above material has been prepared by ZGI for informational purposes only and should not be construed as an offer to sell or solicitation of an offer to purchase or subscribe for any investment. The information and opinions contained in this report have been compiled or arrived at by ZGI in good faith from sources believed to be reliable, but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute ZGI's judgment as of the date of this report and are subject to change without notice. ZGI makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of ZGI only and are subject to change without notice. ZGI does not provide an analysis of a company's financial position; financial position and all information should be verified with the "mentioned company" investor relations department. Information about publicly listed companies and other investor resources can be found at the Securities & Exchange Commission website www.sec.gov. We are not registered investment advisors, or broker/dealers or members of any financial regulatory bodies, and therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The information contained herein is not to be regarded as advice to make any particular investment. In receiving this material, each recipient represents, warrants and acknowledges that it has taken, or will take, appropriate steps to: obtain such independent legal, tax, accounting and other professional advice as may be appropriate prior to taking any action in relation to any companies mentioned; form its own independent judgment regarding the risks and 27A of the Securities Act of 1933 and Sectio

©Copyright 2024 The Zéphirin Group, Inc. ("Z6I"). All rights reserved. This report contains information, text, proprietary information, images, logos and/or other material that is the intellectual property of The Zéphirin Group. Inc. Website: www.zephiringroup.com - www.zephiringroup.中国 - For questions or comments about this report, e-mail us at: info@zephiringroup.com

This report may not be reproduced, distributed or published in electronic, paper or other form for any purpose without the prior written consent of The Zéphirin Group, Inc. Recipients ("YDU") agree to use this research publication solely for their own non-commercial use and benefit, and not for resale or not redistribute or not transfer or recreate the report or any data/information contained in the research publication. Furthermore, recipients may not use any of the trademarks, trade names, service marks, copyrights, or logos of ZGI in any manner which creates the impression that such items belong to and or associated with the recipients. Recipients acknowledge that they have no ownership rights in and or to any such items. No Group Company accepts any liability whatsoever for any direct, indirect or consequential loss arising from any inaccuracy herein or from any use of this report or its contents. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. ZGI accepts no liability whatsoever for the actions of third parties. ZGI makes no representations or warranties whatsoever as to the data and information provided in any third party referenced website and shall have no liability or responsibility arising out of, or in connection with, any such referenced website. Accessing third party portal or website is at your own risk. This publication is made available through Thomson Dne Analytics www.thomsononenim.com first Call research direct portal. This publication is available through Thomson Research Investext http://research.thomsonib.com an Institutional research portal provider. This publication is also made available through Research portal provider. This publication is also made available through S&P Capital IQ www.capitaliq.com a research portal provider. This publication is also made available through Research poot or if they require further information. The distribution. Clients of that institution should contact that institution to affect a tr

Canada. Recipients must comply with all applicable laws and regulations of Canada, including any prohibitions on speculative transactions and currency arbitrage trading. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. No action has been taken by ZGI or any affiliate which would permit services of distribution or re-distribution of this document in Canada. Accordingly, the products and services of such entities are not being offered or sold within Canada by means of this document or any other document.

People's Republic of China ("PRC"). Recipients must comply with all applicable laws and regulations of PRC, including any prohibitions on speculative transactions and currency arbitrage trading. No action has been taken by ZGI or any affiliate which would permit services of distribution or re-distribution of this document in the PRC. Accordingly, the products and services of such entities are not being offered or sold within the PRC by means of this document or any other document. This document may not be distributed, re-distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations. Hong Kong (HK). Recipients must comply with all applicable laws and regulations of the Hong Kong Monetary Authority to conduct Type I (dealing in securities). Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities. The contents of this publication have not been reviewed by any regulatory authority in Hong Kong. This report is for distribution only to professional investors within the meaning of Part I of Schedule I to the Securities and Futures Ordinance of Hong Kong (Cap. 571, Laws of HK) and any rules made thereunder and may not be redistributed in whole or in part in Hong Kong to any person. If in doubt about the contents of this publication, you should obtain independent professional advice.

Other Jurisdictions. THIS MATERIAL DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL
TO DO SO. The distribution of this research in other jurisdictions may be restricted by law and persons into whose possession this research comes should inform themselves about and observe any such restrictions. By accepting this research' the recipient agrees to be bound by the foregoing instructions.

If this publication has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. ZGI do not accept any Liability as a result of electronic transmission of this publication.

ZGI adheres to the CFA Institute (formerly Association for Investment Management & Research) Research Objective Standards guideline.

This report is intended solely for distribution to the professional investment community within the meaning of Rule 15a-6 of the U.S. Securities and Exchange Commission under the Securities Act of 1934. ZGI or any officers, directors does not hold any equity positions in any company or companies mentioned in this report.